British Society of Cinematographers

Tartisan Nickel Corp. Closes the Gross Revenue Royalty, Kenbridge Nickel Project, Northwestern Ontario

Retrieved on: 
Thursday, April 27, 2023
TSX Venture Exchange, Kenbridge, Virginia, Technical report, Resource, Mineral resource estimation, G&A, British Society of Cinematographers, Transaction, Transport, News, Mining, ELEC, NSR, FSE, Barr v. American Assn. of Political Consultants, Inc., Nickel, National Instrument 43-101, Cobalt, Techno-economic assessment, GRR, CSE, PEA, First Nations, Mineral Resources Limited, Technical, Talc, Mineral, Partnership, Metal, Consultant, Nature, Škoda 19 T, Copper, Tunnel, Extractive metallurgy, Uranium mining, Typesetting, New Gold

Mark Appleby, CEO of Tartisan Nickel Corp. states, "Electric Royalties has a growing portfolio of 21 royalties, including two royalties that currently generate revenue.

Key Points: 
  • Mark Appleby, CEO of Tartisan Nickel Corp. states, "Electric Royalties has a growing portfolio of 21 royalties, including two royalties that currently generate revenue.
  • We look forward to our partnership with Electric Royalties as Tartisan Nickel Corp. enters the advanced exploration, feasibility & project development stage."
  • 1 Technical report titled "Preliminary Economic Assessment of the Kenbridge Nickel Project, Kenora, Ontario" with an effective date of July 6, 2022, available under Tartisan Nickel Corp.'s profile on Sedar.com .
  • 2 Technical report titled "Preliminary Economic Assessment of the Kenbridge Nickel Project, Kenora, Ontario" with an effective date of July 6, 2022, available under Tartisan Nickel Corp.'s profile on Sedar.com .

Electric Royalties Ltd. to Acquire 0.5% Gross Revenue Royalty on Kenbridge Nickel Project in Ontario, Canada

Retrieved on: 
Monday, March 6, 2023
Metal, Škoda 19 T, Nickel, Mineral Resources Limited, Transaction, British Society of Cinematographers, Mineral, Mineral resource estimation, Consultant, Technical, Acquisition, Electricity, Copper, Workforce, TSX Venture Exchange, First Nations, Partnership, Techno-economic assessment, Nature, GRR, Mining, Cobalt, G&A, Barr v. American Assn. of Political Consultants, Inc., CSE, Technical report, Employment, FSE, PEA, Transport, NSR, Kenbridge, Virginia, ELEC, Talc, National Instrument 43-101, Resource, News, Tunnel, Extractive metallurgy, Uranium mining, Nursing, Typesetting, New Gold

Electric Royalties will also have the option, for a period of 18 months after closing of the Transaction, to acquire a further 0.5% GRR on the Kenbridge Nickel Project for C$1,750,000 cash consideration.

Key Points: 
  • Electric Royalties will also have the option, for a period of 18 months after closing of the Transaction, to acquire a further 0.5% GRR on the Kenbridge Nickel Project for C$1,750,000 cash consideration.
  • Brendan Yurik, CEO of Electric Royalties commented, "We're excited to partner with Tartisan Nickel on advancing the Kenbridge nickel-copper-cobalt project in Ontario.
  • Mark Appleby, CEO of Tartisan Nickel Corp. states, "Electric Royalties has a growing portfolio of 21 royalties, including two royalties that currently generate revenue.
  • We look forward to our partnership with Electric Royalties as Tartisan Nickel Corp. enters the feasibility, project development stage."

CADTH Recommends Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada

Retrieved on: 
Wednesday, March 8, 2023
MD, BioCryst Pharmaceuticals, PARK, Health Canada, Patient, CADTH, Disease, Hereditary angioedema, FRCPC, British Society of Cinematographers, HAE, CDEC, RESEARCH, Pharmaceutical industry, Health insurance

RESEARCH TRIANGLE PARK, N.C., March 08, 2023 (GLOBE NEWSWIRE) --  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) has issued a positive recommendation for ORLADEYO® (berotralstat) to be reimbursed for the routine prevention of attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older.

Key Points: 
  • In issuing this positive recommendation, CADTH is opening the door to many Canadian HAE patients being able to access ORLADEYO,” said Stephen Betschel, HBSc, MD, FRCPC, FAAAAI, Chair of the Canadian Hereditary Angioedema Network.
  • “BioCryst is delighted that ORLADEYO has received this positive recommendation from CADTH.
  • Health Canada authorized ORLADEYO in June 2022 for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older.
  • The full CADTH reimbursement recommendation for ORLADEYO is available on CADTH’s website .